A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.

Completed

Looking for future studies?

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hirosaki-shi, Aomori, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Those judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion criteria

Those with concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease etc.
Others who are assessed to be ineligible for the study by the investigator or subinvestigator.

Treatment and study plan

AD-4833 15 mg

Drug

AD-4833 30 mg

Drug

Placebo

Drug

Primary outcomes

Glycosylated Hemoglobin (HbA1c)

Time frame: 16 weeks

Measurement of change in HbA1c (ratio of hemoglobin bound to glucose)

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

A Phase 4, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of AD-4833 When Orally Administered Once Daily as add-on to SYR-322 Versus SYR-322 Alone in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With SYR-322 in Addition to Diet and/or Exercise Therapy

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Sep 18, 2012
Registry last updated: Aug 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed